HeartBeam (NASDAQ: BEAT), a developmental stage digital health care company with a proprietary ECG telemedicine technology for heart attack detection, today announced that it will host a virtual roadshow webinar. During the event, scheduled to take place at 4:30 p.m. ET on Tuesday, Sept. 20, 2022, a new video showcasing the HeartBeam AIMIGo platform technology for use in heart attack detection will be unveiled. HeartBeam’s CEO and founder Branislav Vajdic, PhD, CFO Rick Brounstein, and Chief Business Officer Jon Hunt, PhD, will host the webinar and review recent announcements, including the company’s 510(k) application to the FDA for its HeartBeam AIMI(TM) platform technology, and discuss ongoing initiatives and key 2022 and 2023 milestones. Interested parties should dial 1-877-704-4453 or 1-201-389-0920 (international) and enter conference code: 13732771 and visit https://ibn.fm/G3ZAP to access the webinar. A telephone replay will be made available via the webcast link and on the company’s website as detailed in the announcement.

To view the full press release, visit https://ibn.fm/91dkS

About HeartBeam Inc.

HeartBeam is a development stage digital health care company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack. For more information, visit www.HeartBeam.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork